Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer

Table 1 Detailed information of pancreatic cancer patients treated with stereotactic body radiotherapy

Patient	Sex	T	N	M	CA19-9	Dose/No. of fractions	Live/dead	Survival time (mo)	Toxicity
1	Female	4	0	0	Positive	36 Gy/3	Live	4	G1
2	Male	3	0	0	Negative	45 Gy/4	Dead	9
3	Male	3	1	1	Negative	48 Gy/4	Live	2	G1
4	Male	3	0	0	Positive	46 Gy/4	Dead	2
5	Male	3	1	1	Positive	46 Gy/4	Dead	8
6	Male	3	1	1	Positive	30 Gy/3	Live	8	G1
7	Female	3	0	0	Positive	36 Gy/3	Dead	4
8	Female	3	1	0	Negative	31.5 Gy/3	Live	17
9	Female	3	1	1	Negative	33 Gy/3	Dead	5
10	Male	3	0	1	Positive	36 Gy/3	Dead	9	G1
11	Male	3	0	1	Positive	35 Gy/3	Dead	14
12	Female	4	1	1	Positive	33 Gy/3	Dead	9
13	Female	4	0	1	Positive	36 Gy/3	Dead	3	G1
14	Male	3	0	0	Positive	36 Gy/3	Live	6
15	Male	3	0	1	Negative	40 Gy/4	Dead	3
16	Female	3	0	1	Positive	45 Gy/4	Live	15	G1
17	Male	3	1	1	Negative	33 Gy/3	Dead	17
18	Male	3	0	1	Positive	36 Gy/3	Dead	2	G2
19	Male	3	1	1	Positive	36 Gy/3	Dead	2
20	Male	3	1	0	Negative	42 Gy/4	Dead	3
21	Male	3	0	0	Negative	33 Gy/3	Live	3	G1
22	Male	4	1	1	Positive	40 Gy/4	Live	1
23	Male	3	1	0	Positive	46 Gy/4	Live	25
24	Male	3	1	1	Negative	48 Gy/4	Dead	9
25	Male	3	0	1	Positive	40 Gy/4	Live	9	G1

CA19-9: Carbohydrate antigen 19-9.